Nidhi Shashikumar is a data scientist and business intelligence expert with over 7 years of experience in healthcare ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

OSU Marion graduate, Mount Gilead native Kaitlynn Pfeifer accepted into mock in vitro fertilization lab in North Carolina.

Mount Gilead and Gilead Township will go forward with plans for a 23-acre solar installation following its approval by the ...

Winners of the $500 scholarships, made possible by the MOESC Board of Governors, were awarded to Rebekah Case (Lucas Local ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

A four-time podium All-Ohio finisher who was the Division III state runner-up in boys cross country, Baker added to his medal ...

More than 13,000 votes were cast in the eight Marion Star 2024-25 Athlete of he Year polls for winter sports. Here is how the nominees fared: ...

Josh Brown, CEO of Ritholtz Wealth Management, said during a program on CNBC last month that he’s paying attention to Gilead Sciences Inc (NASDAQ:GILD).

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...